USP Method for Felodipine ER Tablets

This method presents the USP Felodipine Extended-Release Tablet assay using the Cogent RP C18. As shown in the chromatogram with a five injection overlay, the peak efficiency is superb and USP peak tailing guidelines are easily met with the Cogent RP C18™ column.  This demonstrates a great alternative Column for easy plug and play or alternate for this USP Method.


Method Conditions:
Column: Cogent RP C18™, 5μm, 100Å
Catalog No.: 68518-15P
Dimensions: 4.6 x 150 mm
Buffer: 6.9 mg/mL of Monobasic Sodium Phosphate in Water. Adjust with 1 M Phosphoric Acid to a pH of 3.0 ± 0.05
Mobile Phase: Acetonitrile, Methanol, and Buffer (40:20:40)
Injection vol.: 40μL
Flow rate: 1.0 mL/minute
Detection: UV @ 362 nm
Sample: Standard solution: 0.02 mg/mL of USP Felodipine in Mobile phase

Most recently appeared in Pharmacopeial Forum: Volume No. 43(6) Page Information:
USP43-NF38 – 1827
USP42-NF37 – 1787
USP41-NF36 – 1690

Note: Felodipine is a calcium channel blocker and acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. Felodipine prevents myocyte contraction by binding to calcium-binding proteins, which exhibits competitive antagonism of the mineralcorticoid receptor. This event results into inhibiting the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase and blocking calcium influx through voltage-gated T-type calcium channels. This reduces movement of calcium into the cells of the heart and blood vessels and increases supply of blood and oxygen to the heart.


No. 387 Felodipine Extended Release USP Method pdf  84.7 Kb  Download File